REPORTS FROM THE FIELD

Surgical tourniquet co HemaClear targets Nasdaq IPO

Globes, Jan 18th 2012

For more information please Click Here

HemaClear is looking for strategic cooperation and new technologies (Hebrew Press Release)

Published in Globes, Israel Jan 17th, 2012

Read Article (Hebrew)

HemaClear® Recommended to NICE as Standard of Care in Bloodless Orthopedic Surgery

Press Release, Source: OHK Medical Devices, Inc. Haifa, Israel (PRWEB) November 23, 2011.

HemaClear® today announced that its proprietary disposable tourniquet solution has been recommended to the National Institute for Health and Clinical Excellence (NICE) as a standard of care in bloodless orthopedic limb surgery. HemaClear® was recommended as a new and necessary guideline for prevention of Surgical Site Infection (SSI), as part of a clinical study published last week in the Annals of The Royal College of Surgeons of England.

The study, ”The Effect of Sterile Versus Non –Sterile Tourniquets on Microbiological Colonization in Lower Limb Surgery”, conducted by researchers at St. Peter’s Hospital in Chertsey, UK, is the first to compare the microbiological colonization load of reusable pneumatic tourniquet solutions versus the single use HemaClear® exsanguinating surgical tourniquet, in total knee arthroplasty. Samples of both types of tourniquets were taken at the end of the procedures, sealed, cultured and then incubated.

The results of the study showed that HemaClear® was bacteria free in all cases preformed, not only prior to application, but also at the end of the procedure. 68% of the pneumatic tourniquets, on the contrary, were shown to be contaminated by an array of bacteria.

Half of the bacteria loaded pneumatic tourniquets were contaminated with the bacteria Staphylococcus app. This bacterium is the single most common cause for infection in total knee replacement and arthroscopy, causing alone an infection rate of 1%-3% of knee procedures. Other bacteria present on the pneumatic tourniquet included Bacillus spp, coliform, and Sphingomonas paucimobilis. Bacteria cause surgical site infections which are associated with an acute increase in patient related costs, as well as poor clinical outcome and prolonged patient hospitalization.

The research team concluded the study by stating that “The availability of an alternative (tourniquet solution) should now set the new standard of care and we recommend adopting this as a current NICE guideline for control of SSI”. For more information regarding the study, please refer to http://www.ncbi.nlm.nih.gov/pubmed/22041233.

About HemaClear Headquartered in Haifa, Israel, HemaClear® is the no buttons, no tubing, no electricity, no smell, no beeps or leaks surgical tourniquet that creates a bloodless field in seconds. HemaClear's simple, innovative and cost-effective technology replaces traditional devices, completely eliminating the need for a tourniquet machine, tourniquet cuff, Esmarch bandage, Webril™ and stockinet. It is the first and only disposable tourniquet with controlled pressure, effective exsanguination, and complete sterility that saves operating room time, reduces risks of infection and enhances surgical performance. Hemaclear is used as a standard of care for bloodless orthopedic surgery in over 25 countries and over 250,000 of Hemaclear’s tourniquets have been applied. Over 15 clinical publications have been published, documenting the different ease of use, clinical and safety advantages of the product.

For more information, visit the HemaClear site at http://www.Hemaclear.com, visit http://www.youtube.com/watch?v=clYxiOGhj5Y or join the Facebook page of the company's mascot, Henry HemaClear, a virtual sales representative and superhero overcoming non-sterile operating procedures worldwide.

Contact:
Grant Castor
U.S. National Sales Manager
Grant(at)hemaclear(dot)com
(267) 549-8797

Omer Inbar
International Sales Manager
Omer(at)hemaclear(dot)com
(972) 54-7827289

OHK Medical Devices Selects Henry Schein as Exclusive Distributor of HemaClear

Press Release, Source: OHK Medical Devices, Inc. On Wednesday February 16, 2011, 5:25 pm EST, NEWARK, N.J.

OHK Medical Devices, Inc. announced today that it has selected Henry Schein Medical, the U.S. physician business of Henry Schein Inc. (Nasdaq:HSIC - News), the largest distributor of health care products and services to office-based dental, medical and veterinary practitioners, as the exclusive distributor of HemaClear® for the U.S. alternate care market. HemaClear is the first and only surgical tourniquet single-use device that exsanguinates, occludes, and provides a clearer surgical field.

"HemaClear is delighted to be partnering with a company that has such an excellent reputation for bringing its customers the highest quality and most innovative products on the market," said Oren Gavriely, Chief Executive Officer, OHK Medical Devices. "We are very much looking forward to bringing this new, revolutionary standard of care to Henry Schein customers around the country."

An exsanguination device that prepares any limb for surgery in less than 12 seconds, HemaClear provides a larger, dryer, and clearer surgical field, thereby providing the surgeon with a better view of anatomical structures. Its ease of use and simplicity saves valuable operating room time. HemaClear has been proven worldwide in over 180,000 surgical cases.

"Henry Schein Medical is pleased to exclusively offer HemaClear as part of our ongoing commitment to help drive the success of our customers' practices and enable them to provide the highest quality care," said Dave McKinley, President of Henry Schein Medical. "This innovative new technology is simple, sterile, safe, cost-effective, and ultimately provides more successful surgical outcomes, especially for our customers that practice in ambulatory surgical settings and perform office-based procedures."

About HemaClear

Manufactured by OHK Medical Devices, Inc., headquartered in Haifa, Israel, HemaClear® is the first self-contained, sterile, exsanguinating tourniquet that creates a bloodless field in seconds. HemaClear® performs three functions: blood removal (exsanguination), arterial flow occlusion, and automatic application of the sterile stockinet. HemaClear® replaces traditional devices, completely eliminating the need for a tourniquet machine, tourniquet cuff, Esmarch bandage, Webril™ and stockinet.

Perhaps most advantageous of all, from a logistics point of view, HemaClear® is self-contained and requires absolutely no connections or power source. HemaClear's innovative technology not only reduces blood loss, infection, and the volume of ischemic tissue, its simplicity saves precious operating room set-up time‚ as much as fifteen minutes‚ and over 10 separate steps and products that can save as much as $300 a procedure.

Hemaclear is used as a standard of care in over 25 countries and over 180,000 of Hemaclear's tourniquets have been applied. For more information, visit the HemaClear site at www.Hemaclear.com, or visit http://www.youtube.com/watch?v=L46SI03Lpl0

About Henry Schein

Henry Schein, Inc. (Nasdaq:HSIC - News), the largest provider of health care products and services to office-based practitioners, is a Fortune 500® company and a member of the NASDAQ 100® Index. The Company is recognized for its excellent customer service and highly competitive prices. Henry Schein's five businesses – North American Dental, North American Medical, North American Animal Health, International and Technology – serve more than 700,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items. Henry Schein also provides exclusive, innovative technology offerings for dental, medical and veterinary professionals, including value-added practice management software and electronic health record solutions.

Headquartered in Melville, N.Y., Henry Schein employs more than 14,000 people and has operations or affiliates in 24 countries. The Company's net sales reached a record $6.5 billion in 2009. For more information, visit the Henry Schein Web site at www.henryschein.com.

-------------------------------------------------

Healthcare co OHK signs with major US distributor

Gali Weinreb Published by Globes [online], Israel business news - on February 16, 2011

OHK Medical Devices Ltd., has signed an exclusive marketing agreement with Henry Schein Inc. (Nasdaq: HSIC) for Hemaclear, an innovative tourniquet to create a bloodless field for limb surgery.

Henry Schein is one of the largest distributors of medical devices in the US, and has a market cap of $6.3 billion. It also distributes the dental surgical products of Sialo Technology Israel Ltd. (TASE: SALO).

OHK CEO Oren Gavriely founded the company on the basis of an invention by his father, Dr. Noam Gavriely. Noam Gavriely is also behind the inventions on which ET View Medical Ltd. (TASE: ETVW) and KarmelSonix Ltd. (ASX: KSX) are based. OHK currently only focuses on the Hemaclear tourniquet.

Shlomo Ben-Haim is one of OHK's investors. He is a founder of Biosense Webster Inc., Impulse Dynamics NV, InStent Inc., and Disc-O-Tech Ltd., which were sold for over $1 billion altogether. He currently manages nine portfolio companies through Medinvest, and invests in early-stage companies.

The largest investor in OHK is Italy's IP Medical. OHK has raised $4.5 million to date.

Hemaclear is a small and fairly cheap product designed to replace heavy and expensive tourniquet systems to create blood-free environments for limb surgery. The company has independently sold 150,000 Hemaclear units to date to hospitals, generating $3 million revenue, mostly in Europe. The company has 20 employees.

Henry Schein bought exclusive distribution rights to the Hemaclear to non-hospital clinics, which often carry out simple limb surgical procedures, but which cannot afford expensive tourniquets.

OHK plans to add other activities ahead of an IPO, not necessarily in Israel, in 2012.

Published by Globes [online], Israel business news - www.globes-online.com - on February 16, 2011

Hemaclear® is exhibiting at the American Academy for Orthopedic Surgery 2011, Feb 15-18, booth No.5833.

Please come on by and learn more about HemaClear® from User Dr. Wayne Goldstein - University Of Illinois At Chicago on Friday Feb 18th, 2011 10:30 AM.

OHK Medical Devices Donating HemaClear to Support Medical Teams in Haiti.

NEWARK NJ, Jan. 12 - OHK Medical Devices today announced that it will provide donations of HemaClear products to medical teams and relief agencies working in Haiti with victims of the catastrophic earthquake on January 12.

"It is important that surgeons and medical teams working in the field have access to the best available technology" said Oren Gavriely, CEO of OHK Medical Devices. "The large number of crush injuries will require some type of orthopedic surgery. HemaClear is the ideal device for this purpose. We believe it is our responsibility to contribute and assist with the healing efforts."

OHK has already sent HemaClear devices with three medical teams that will be operating in Haiti in the next few days. Medical teams from the Hospital for Special Surgery in NYC, Sinai Hospital in Baltimore and Ocala FL all requested product suitable for both upper and lower limbs. OHK is now reaching out to its entire user base in the US and Europe offering similar donations to support orthopedic missions in Haiti and elsewhere around the world.

OHK Medical Completes $1.8 Million Investment Round

Company on track for reaching positive cash flow in the coming quarters

Haifa, Israel, 28 September 2010. OHK Medical Devices Ltd. (OHK), today announced the closing of a Series-B investment, totaling $1.8 million[1].

The investment round was led by IP Medical Capital, an Italian private equity firm , together with a group of current shareholders. IP is a Milan-based private and independent investment company founded and owned by the Denegri Family. IP has been highly successful in selecting promising companies, and leading them to commercial success, providing their investors with a lucrative return on investment.

The funds raised will be used to expand OHK's marketing and sales efforts, particularly in the United States, as well as scale up manufacturing to meet expected demand. In addition, the Company will be leveraging the funds to strengthen its R&D capabilities and develop new, and related, technologies.

Mr. Michele Denegri, IP Medical Capital's General Manager, who will join OHK's Board of Directors, commented: "We are very pleased with this unique opportunity to invest and support a company with significant potential for transforming its market, which has already shown very strong traction and growth. We are joining forces with a leading group of shareholders and the highly experienced leadership of OHK. Management has already demonstrated its strong abilities in penetrating its market with innovative products, by identifying and meeting a true market need and establishing a clear commercial beach-head in formerly conservative market."

Oren Gavriely, CEO and Founder of OHK Medical commented, "We are delighted that IP has joined our group of leading and value-adding shareholders, and we look forward to their long-term support over the coming years. Our business continues to grow quickly as our products increasingly gain traction and market share. We expect to become cash-flow positive in the coming quarters, built on our continued growth in revenue and improving financial metrics."